CN111983240B - Visual detection method for clostridium perfringens alpha toxin - Google Patents
Visual detection method for clostridium perfringens alpha toxin Download PDFInfo
- Publication number
- CN111983240B CN111983240B CN202010883292.3A CN202010883292A CN111983240B CN 111983240 B CN111983240 B CN 111983240B CN 202010883292 A CN202010883292 A CN 202010883292A CN 111983240 B CN111983240 B CN 111983240B
- Authority
- CN
- China
- Prior art keywords
- cpa
- antibody
- detection
- alpha toxin
- clostridium perfringens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010081427 Clostridium perfringens alpha toxin Proteins 0.000 title claims abstract description 118
- 238000001514 detection method Methods 0.000 title claims abstract description 59
- 230000000007 visual effect Effects 0.000 title claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000004005 microsphere Substances 0.000 claims abstract description 22
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 16
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000008878 coupling Effects 0.000 claims abstract description 11
- 238000010168 coupling process Methods 0.000 claims abstract description 11
- 238000005859 coupling reaction Methods 0.000 claims abstract description 11
- 238000001917 fluorescence detection Methods 0.000 claims abstract description 10
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 238000012545 processing Methods 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 241000193403 Clostridium Species 0.000 claims abstract description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 3
- 239000002776 alpha toxin Substances 0.000 claims description 22
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 21
- 101710197219 Alpha-toxin Proteins 0.000 claims description 21
- 101710124951 Phospholipase C Proteins 0.000 claims description 21
- 238000010790 dilution Methods 0.000 claims description 19
- 239000012895 dilution Substances 0.000 claims description 19
- 238000002474 experimental method Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 238000002073 fluorescence micrograph Methods 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 230000009465 prokaryotic expression Effects 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 230000000903 blocking effect Effects 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 102220362486 c.167A>G Human genes 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 101150105088 Dele1 gene Proteins 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 231100000225 lethality Toxicity 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 230000001018 virulence Effects 0.000 claims description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 abstract description 25
- 231100000765 toxin Toxicity 0.000 abstract description 25
- 238000011897 real-time detection Methods 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 26
- 241000193468 Clostridium perfringens Species 0.000 description 16
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000147 enterotoxin Substances 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 101710139849 Alpha-toxin 4 Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 231100001102 clostridial toxin Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 1
- DKQCWCQRAMAFLN-UBHSHLNASA-N Asp-Trp-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O DKQCWCQRAMAFLN-UBHSHLNASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- SXIJQMBEVYWAQT-GUBZILKMSA-N Gln-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXIJQMBEVYWAQT-GUBZILKMSA-N 0.000 description 1
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 1
- HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 1
- LJLPOZGRPLORTF-CIUDSAMLSA-N Glu-Asn-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LJLPOZGRPLORTF-CIUDSAMLSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- DAHLWSFUXOHMIA-FXQIFTODSA-N Glu-Ser-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O DAHLWSFUXOHMIA-FXQIFTODSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- LGQZOQRDEUIZJY-YUMQZZPRSA-N Gly-Cys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CS)NC(=O)CN)C(O)=O LGQZOQRDEUIZJY-YUMQZZPRSA-N 0.000 description 1
- UTYGDAHJBBDPBA-BYULHYEWSA-N Gly-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN UTYGDAHJBBDPBA-BYULHYEWSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- MBSSHYPAEHPSGY-LSJOCFKGSA-N His-Ala-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O MBSSHYPAEHPSGY-LSJOCFKGSA-N 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- CTEMYIWDSVICKS-WDSOQIARSA-N His-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N CTEMYIWDSVICKS-WDSOQIARSA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- DGAAQRAUOFHBFJ-CIUDSAMLSA-N Lys-Asn-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DGAAQRAUOFHBFJ-CIUDSAMLSA-N 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- GRADYHMSAUIKPS-DCAQKATOSA-N Lys-Glu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRADYHMSAUIKPS-DCAQKATOSA-N 0.000 description 1
- LHXFNWBNRBWMNV-DCAQKATOSA-N Met-Ser-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LHXFNWBNRBWMNV-DCAQKATOSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- JLDZQPPLTJTJLE-IHPCNDPISA-N Phe-Trp-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JLDZQPPLTJTJLE-IHPCNDPISA-N 0.000 description 1
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 1
- LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
- UQGAAZXSCGWMFU-UBHSHLNASA-N Ser-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N UQGAAZXSCGWMFU-UBHSHLNASA-N 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- DIHPMRTXPYMDJZ-KAOXEZKKSA-N Thr-Tyr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N)O DIHPMRTXPYMDJZ-KAOXEZKKSA-N 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- OSMTVLSRTQDWHJ-JBACZVJFSA-N Tyr-Glu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 OSMTVLSRTQDWHJ-JBACZVJFSA-N 0.000 description 1
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 description 1
- GYKDRHDMGQUZPU-MGHWNKPDSA-N Tyr-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GYKDRHDMGQUZPU-MGHWNKPDSA-N 0.000 description 1
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
- QPOUERMDWKKZEG-HJPIBITLSA-N Tyr-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QPOUERMDWKKZEG-HJPIBITLSA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- -1 carboxyl modified silica microspheres Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 101150085553 cpb-2 gene Proteins 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010029599 tyrosyl-glutamyl-tryptophan Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a visual detection method for clostridium perfringens alpha toxin, which combines a smart phone image processing technology and silica microsphere antibody coupling detection for food-borne clostridium perfringens alpha toxin (CPA). According to the double-antibody sandwich principle, the prepared CPA polyclonal antibody is coupled with the silicon dioxide microsphere, CPA fluorescence detection is carried out through FITC fluorescence marked by the antibody, and finally, the real-time detection of CPA content is realized by combining with the image processing technology of the smart phone APP. Compared with the traditional clostridium toxin detection method, the nano microsphere combined smart phone CPA detection system is a more sensitive, stable and convenient detection method, and provides a new method for detecting natural CPA in food.
Description
Technical Field
The invention belongs to the field of biotechnology, and relates to a detection method of food-borne pathogenic bacteria clostridium perfringens alpha toxin.
Background
Clostridium perfringens shapeBacillus (Clostridium perfringens), also known as food-borne gastroenteritis and other infectious diseases. As a conditionally pathogenic bacterium, it can contaminate many types of retail meat products and produce alpha toxins in the small intestine of livestock [1] Food poisoning may result when milk and dairy products contaminated with such bacteria or toxins are consumed. Clostridium perfringens causes a variety of diseases in various hosts due to the production of various toxins and extracellular enzymes [2] . To date, at least 20 exotoxins have been found, of which the major deadly toxins are α, β, ε and iota. Because all types of toxins produce alpha toxin and result in hemorrhagic enteritis and acute death in livestock [3] And alpha toxin is the most important virulence factor of clostridium perfringens type a [4] . It has cytotoxicity, hemolytic activity, lethality, skin necrosis, and myonecrosis [5] Granulocytogenesis [6] Erythroid differentiation inhibition [7] Platelet aggregation and increased vascular permeability.
The detection of clostridium perfringens is currently mainly based on molecular biological assays PCR or immunological assays ELISA, etc. Oisvik et al established a four-layer sandwich method for the detection of clostridium perfringens enterotoxins. This method can detect enterotoxins at 0.1 μg/mL, but the entire experiment takes 4 days to complete. McClane et al [8] Established indirect ELISA methods can detect enterotoxins of 25ng/mL and shorten the experimental time. Hale et al [9] An antigen capture ELISA method is established for detecting clostridium perfringens toxin, and has good specificity and sensitivity, and the minimum detection amount of alpha toxin is 19ng/mL. These methods can be used to diagnose Clostridium perfringens using PCR techniques instead of serum neutralization assays [10] The toxin content of goat feces and gastrointestinal tract was successfully detected. In 1997, a PCR technique was established to determine four different toxins in goat feces. However, the method established by Uzal is cumbersome and uneconomical and the sample needs to be tested four times. Yoo et al [11] Multiplex PCR was established to detect the four main toxins of clostridium perfringens, but this method requires extraction and purification of the bacterial genome. Baums CG and the like [12] Establishes a kind ofA multiplex PCR method capable of typing clostridium perfringens, which can directly detect and distinguish between cpa (alpha), cpb (beta 1), etx (epsilon), iap (iota), cpe (enterotoxin) and cpb2 (beta 2) and other toxin genes, and has good specificity and reproducibility. Furthermore, gurjar et al [13] Fluorescent quantitative PCR was established. The main toxin genes of clostridium perfringens can be detected directly from fecal samples and can be used for epidemiological investigation of diseases. In summary, the sensitivity of the existing technology for detecting clostridium perfringens by ELISA is high, the minimum detection limit can reach 19ng/mL, but the common problem is that the operation process is time-consuming and complicated; the PCR method can be used for simultaneously detecting various clostridium perfringens toxins, but the toxins need to be purified in the detection process, and the sensitivity is low, and the detection is time-consuming and tedious. Therefore, it is necessary to establish a highly efficient, sensitive, and convenient detection system for clostridial toxins.
Disclosure of Invention
The invention aims to provide a visual detection method for clostridium perfringens alpha toxin, which is used for solving the problems of low detection limit, long time, and the like in the prior art and making up for the defect of single detection technology.
The invention aims at realizing the following technical scheme:
a visual detection method for rapidly detecting food-borne clostridium perfringens alpha toxin in real time based on combination of silica microspheres and a smart phone comprises the steps of preparing antibodies by injecting a prokaryotic-expressed CPA truncated protein into animals, coupling the antibodies with the silica microspheres after Fluorescein Isothiocyanate (FITC) labeling, capturing alpha toxin in food, uploading a fluorescent picture obtained by detection to a mobile phone APP, and immediately obtaining the concentration of the alpha toxin in a sample to be detected in real time.
The prokaryotic expression CPA protein truncated CPA N Comprises two mutation sites (D56G, D130G) of CPA protein, and the preparation of the antibody N The protein sequence of the truncated SEQ ID No. 1.
The method comprises the following main steps:
(1) CPA protein truncate CPA N Is constructed by the following steps: due to CPA eggsWhite is toxic and lethal, and to facilitate subsequent antisera preparation, mutants of CPA were used in experiments to eliminate toxic effects on immunized animals. The complimentary 4-amino acid mutant plasmid (pET 30 a-CPA) was taught by Chen Xiaoyun m4 ) And a C-terminal three-copy tandem plasmid (pET 30a-CPA C3 ) [14,15] . In CPA m4 Primers (CPA) were designed based on m4 Dele TM-F, SEQ ID No.2 and CPA m4 Delete the transmembrane domain of delete TM-R, SEQ ID No. 3) to obtain N-terminal truncated plasmid pET30a-CPA N The plasmid contains only two amino acid mutations (D56G, D130G).
(2) Antibody preparation: the constructed pET30a-CPA N pET30a-CPA given away by Chen professor C3 The prokaryotic expression vector converts competent cells of escherichia coli BL21 (DE 3), IPTG induces and purifies recombinant proteins. Immunization of rabbits three times with 1mg/mL protein amount resulted in anti-CPA C3 And CPA (CPA) N The polyclonal antibody was purified from rabbit serum by Saturated Ammonium Sulfate (SAS) precipitation and the antibody titer was detected by Western blot and ELISA.
(3) CPA using semi-permeable membrane process N The general principle of the coupling and fluorescence detection of the subsequent silica microspheres is shown in figure 7, and the fluorescence intensity of the microspheres detected by a fluorescence microscope is the concentration of the corresponding clostridium alpha toxin by utilizing the antigen-antibody combined double-antibody sandwich principle.
The CPA protein truncated silica microsphere coupling comprises the following steps:
(1) Quantification of clostridium perfringens alpha toxin using virulence substitution experiment-lecithin hydrolysis experiment, and final measured natural CPA concentration of 10LD 50 。
(2) Activation of silica microspheres: carboxylated silica microsphere surface coupling CPA N Polyclonal antibody, adding coupling agent N-hydroxysuccinimide (NHS) and carbodiimide (EDC) with final concentration of 10mg/mL, and finally blocking.
(3) Condition optimization of silica microsphere detection experiment: the optimal conditions for the fluorescence detection experiment are determined according to the experimental data, namely at 2Capture antibody (CPA) at 0.1mg/ml at 5 ℃ C3 ) After 2h interaction with activated silica microspheres, blocking overnight at 4℃with 5% BSA, alpha toxin and 0.2mg/ml detection antibody (FITC-CPA N ) And (3) performing interaction with the silica microspheres coupled with the capture antibody for 1h, so as to perform detection by a fluorescence microscope.
Establishment of alpha toxin capture standard curve, detection line sensitivity of 0.625LD 50 The detection time was about 90min.
The method comprises the following steps:
(1) Establishment of a standard curve: a double gradient dilution of clostridium perfringens alpha toxin (CPA) was performed for a total of 5 dilutions, each dilution being 3 biological replicates, after which a set of fluorescence images was obtained by detecting the fluorescence intensity of silica microspheres coupled to FITC-labeled antibodies.
(2) The fluorescence intensity in the picture is subjected to gray value analysis (conventional image analysis software such as Photoshop, imageJ and the like is used), the research uses ImageJ software to perform gray value analysis, firstly, the picture is converted into an 8-bit gray image and background interference is eliminated, then brightness values in all image areas are selected for average analysis, finally, the average gray value of the corresponding image is obtained, and data are arranged to obtain a regression equation Y=0.01915X+0.002875 (R 2 = 0.9972). Wherein X represents LD 50 Y represents an average gray value.
(3) The image processing technology is programmed into the intelligent mobile phone APP, the general principle is that the picture is firstly subjected to RGB value analysis, then the RGB color value is converted into hexadecimal color code (gray), so that the gray value of the image is obtained, and finally, different gray value ranges are corresponding to CPA concentration by using an IF algorithm. After APP is prepared, the corresponding CPA concentration can be directly obtained by uploading the fluorescence image.
Based on the method, the invention claims a method for detecting clostridium perfringens alpha toxin in real time by combining the silicon dioxide microspheres with a smart phone.
The invention has the beneficial effects that: the invention prepares the alpha toxin antibody with FITC label and the alpha toxin antibody with FITC label according to the double-antibody sandwich methodA method for detecting food-borne clostridium perfringens alpha toxin by coupling silica microspheres. And analyzing and processing the fluorescence micrograph through APP software which is universal to the android smart phone, so that the alpha toxin content can be determined. The minimum detection limit of the method is 0.625LD 50 The whole detection time is less than or equal to 90min. The overall data processing time was < 5 seconds. The method has the advantages of good stability, high sensitivity, convenient and quick operation and the like, and provides a new thought and direction for detecting the food-borne clostridium perfringens alpha toxin.
Drawings
Fig. 1: CPA recombinant protein CPA C3 And CPA (CPA) N SDS-PAGE results of expression and purification; (a) CPA (CPA) C3 Expression electrophoretogram of recombinant protein. Lanes 1-2 are purified CPA C3 2 samples of recombinant protein; (b) CPA (CPA) N Electrophoresis results M of recombinant proteins: protein molecular Mass Standard (Blue Plus) lanes 3-4 are purified CPA N Two parallel samples of recombinant protein;
fig. 2: clostridium perfringens alpha toxin (CPA) C3 And CPA (CPA) N ) Is determined by the concentration and titer of polyclonal antibodies;
(a) An antibody concentration standard curve measured by Bradford method;
(b) Recombinant protein CPA C3 Western blot results of (M: protein marker (GenStar M221) lanes 1-2: CPA C3 Recombinant proteins);
(c) Recombinant protein CPA C3 And CPA (CPA) N Western blot of (M: protein marker (GenStar M221) lanes 3-4: CPA N Recombinant proteins);
(d) Recombinant protein CPA C3 Is an indirect ELISA result of (2): detected CPA C3 The titer of the antibody was 1:3200;
(e) Recombinant protein CPA N Is an indirect ELISA result of (2): detected CPA N The titer of the antibody was 1:6400;
fig. 3: degree of hydrolysis of CPA by lecithin hydrolysis;
fig. 4: optimal conditions for silica microsphere fluorescence detection experiments;
(a) Optimal antibody coating conditions were determined (fixed other conditions, selected toxin concentration 10LD50, antibody dilution concentration 0.02, 0.1, 0.5mg/ml, assay temperature and time 37℃for 2h,25℃for 2h,4℃for 12h; 3 biological replicates per group);
(b) Optimal blocking conditions were determined (fixing other conditions, selecting toxin concentration as 10LD50, selecting blocking agent as 5% milk and 5% BSA, selecting experimental temperature and time as 37℃for 2h,25℃for 2h,4℃for 12h; 3 biological replicates per group);
(c) Optimal incubation time and dilution (fixation) of enzyme-labeled antibody, unchanged conditions, toxin concentration of 10LD50, dilution concentration of fluorescent-labeled antibody of 0.05, 0.1, 0.2mg/mL, experiment temperature and time of 37 ℃ for 0.5h,37 ℃ for 1h, and 37 ℃ for 2h, respectively; 3 biological replicates per group experiment);
fig. 5: a fluorescence diagram of CPA detection and an established standard regression equation;
(a) Fluorescence pictures at different toxin concentrations: from left to right, the concentrations are respectively 10LD 50 ,5LD 50 ,2.5LD 50 , 1.25LD 50 ,0.625LD 50 Three biological replicates per concentration gradient (i.e., three columns in the corresponding graph);
(b) Y=0.01915x+0.002875 (R 2 =0.9972)。
Fig. 6: a smart phone APP detection interface;
fig. 7: silica microsphere coupled fluorescent antibody is combined with a smart phone APP detection system principle.
Detailed Description
The invention is further illustrated in the following, in conjunction with the accompanying drawings and specific embodiments.
Example 1 basic preparation of the detection method
Step one, standard strain type A (C57-1) was purchased from a veterinary drug test. Alpha toxin 4 amino acid mutant plasmid (CPA) m4 ) And in alpha toxin (CPA) C3 ) The C-terminal three-copy tandem prokaryotic expression vector (pET 30 a) was constructed by the teachings of Chen Xiaoyun of the China veterinary drug institute [14,15] 。
Because site-directed mutagenesis toxins can greatly reduce the toxicity and lethality of CPA, subsequent preparation of non-lethal rabbit serum antibodies is facilitated.
We then used the existing alpha toxin 4 amino acid mutant plasmid (CPA m4 ) N-terminal truncation construction was performed, so that the constructed expression vector contained two mutation sites (D56G, D130G). Construction of the N-terminal expression vector of CPA, PET30a-CPA, using two primers N The clostridium perfringens alpha toxin gene (Genbank accession number: DQ 202275) was searched for according to Genbank, and the N-terminal truncated primer (CPA) was designed by removing the transmembrane domain m4 Dele TM-F, SEQ ID No.2 and CPA m4 Del TM-R, SEQ ID No. 3), upstream and downstream contain restriction sites for BamHI and Xho I, respectively.
Step two, the constructed prokaryotic expression vector (CPA C3 And CPA (CPA) N ) Expressing and purifying prokaryotic recombinant protein, and immunizing rabbits three times with 1mg/ml protein to obtain the anti-CPA C3 And CPA (CPA) N The polyclonal antibody was purified from rabbit serum by Saturated Ammonium Sulfate (SAS) precipitation and the antibody titer was detected by Western blot and ELISA. The results are shown in FIG. 1, and CPA recombinant protein CPA C3 And CPA (CPA) N Can be expressed normally. As can be seen from FIG. 2, CPA of Clostridium perfringens alpha toxin was measured by the Bradford method C3 And CPA (CPA) N The polyclonal antibody concentration of (C) was 7.02mg/mL and 7.47mg/mL, respectively. FIG. 2-b, c shows the Western blot results of recombinant protein CPA C3 And CPA (CPA) N The specificity is good; FIG. 2-d, e indirect ELISA results showing recombinant protein CPA C3 And CPA (CPA) N Titers of 1:3200 and 1:6400, respectively.
Step three, CPA is carried out by utilizing semi-permeable membrane method N Labeling of antibody Fluorescein Isothiocyanate (FITC) the protein concentration of the antibody solution was corrected to 10mg/mL using 0.025M, pH 9.0 carbonate buffer and placed in a dialysis bag. Simultaneously, the amount of antibody protein 1/20FITC, namely, the amount (mg) required by FITC (Beijing Sotel technologies Co., ltd.) =protein content (mg/mL) ×antibody solution amount (mL) ×1/20 was weighed; FITC was dissolved in 10 times 0.025M antibody solution, pH 9.0 carbon in salt buffer, gently stirred to avoid air bubbles; in dialysis bagsThe antibody was immersed in the FITC solution and allowed to stand at 4℃for 16-18 hours, during which time it was stirred periodically 1-2 times per hour with a magnetic stirrer for a total stirring time of about 6 hours. Taking out the dialysis bag, and putting into 0.01M PH7.2 PBS for dialysis for 4 hours for standby.
And step four, quantifying clostridium perfringens alpha toxin by using a virulence substitution experiment, namely a lecithin hydrolysis experiment. Firstly, mashing and mixing fresh cooked yolk, and adding 1% CaCl 2 Normal saline 40 mg/g and 6% Al (OH) 3 Gel 3ml/g, mix and place in a refrigerator at 4℃overnight. The next day was taken out, and after centrifugation at 720g for 20 minutes, the supernatant was taken as lecithin. With physiological saline (2) 0 、2 -1 、2 -2 、 2 -3 、2 -4 、2 -5 ) The alpha toxin was diluted, 1mL lecithin was added to each dilution, and then left to stand at 37℃1 time. Hours. Negative medium and 1mL lecithin were used as control, at OD 550 The absorbance (turbidity) was measured, and the dilution of each hydrolysis reaction was 1/6.4LD 50 Toxicity, i.e. toxicity 2x/6.4 LD after 2-fold dilution 50 . The final measured natural CPA concentration was 10LD 50 . As a result, as shown in FIG. 3, the hydrolysis degree of CPA was measured by lecithin hydrolysis, three biological replicates were performed for each concentration gradient, and a series of absorbance values were obtained, and since toxicity and hydrolytic turbidity had a stable correlation, the correspondence between the hydrolysis degree and concentration of CPA was calibrated by a curve, and finally CPA at the lowest detectable dilution was compared with formula 2x/6.4 LD 50 The clostridium toxin (undiluted) extracted in the experiment was calculated to be 10LD 50 。
Coupling carboxyl modified silica microspheres with fluorescent antibodies: a certain amount of silica microspheres (particle size 10 μm, tianjin all good tech Co., ltd.) was weighed out to be 0.5: EDC was added in a ratio of 1 to 1:1, adding NHS in proportion, fully mixing and shaking at room temperature. For 20 minutes, then washed with PBS and centrifuged to remove the wash (repeated three times). The optimal experimental conditions for the coupling of the antibody and silica microspheres were then determined.
Example 2: condition optimization of detection methods
Step one, determining optimal coating conditions: the variable is coated antibody (bound silica microsphere antibody CPA) C3 ) Other conditions were fixed, the toxin concentration was chosen to be 10LD 50 (3 replicates per condition) then the fluorescence image was observed by fluorescence microscopy and finally the ratio was obtained by grey value analysis. Finally, optimal coating conditions were determined to be 0.1mg/mL capture antibody and silica microspheres were mixed at 25 ℃ for 2 hours. The results are shown in FIG. 4: optimal conditions for microsphere fluorescence detection experiments; (a) determining optimal antibody coating conditions.
Step two, determining the optimal closed condition: the variables were selected blocking agent (5% nonfat milk powder or 5% BSA), the other conditions were fixed, and the selected toxin concentration was 10LD 50 (3 replicates per condition) and grey values for fluorescent image analysis were obtained. Finally, the optimal sealing conditions were determined to be 5% BSA at 4℃for 12 hours. The results are shown in FIG. 4: optimal conditions for microsphere fluorescence detection experiments; (b) determining optimal closed conditions.
Step three, determining the optimal incubation time and optimal enzyme-labeled antibody (CPA) N ) Is a dilution of (2): the variables are dilution factor (1:50, 1:100, 1:200) of enzyme-labeled antibody and time and temperature fixed, other conditions fixed, selected toxin concentration 10LD 50 (3 biological replicates per condition) and the grey scale value of the fluorescence image was analyzed. Finally, the optimal dilution concentration of the enzyme-labeled antibody was 1:50, and the silica microspheres were allowed to act at 37℃for 1 hour. The results are shown in FIG. 4, and the optimal conditions for microsphere fluorescence detection experiments, namely, at 25℃and 0.1mg/ml capture antibody (CPA C3 ) After 2h interaction with activated silica microspheres, blocking overnight at 4℃with 5% BSA, alpha toxin and 0.2mg/ml detection antibody (FITC-CPA N ) And (3) performing interaction with the silica microspheres coupled with the capture antibody for 1h, so as to perform detection by a fluorescence microscope.
Example 3: establishment of detection method
Step one, performing concentration gradient dilution of toxin CPA, and determining the undiluted state quantitatively in the prior artIs 10LD 50 Then we dilute it in 2-fold series to obtain 10LD 50 ,5LD 50 , 2.5LD 50 ,1.25LD 50 ,0.625LD 50 Each concentration gradient was subjected to 3 biological replicates and the corresponding fluorescence image was obtained by fluorescence microscopy. As a result, see FIG. 5, CPA was diluted in a gradient to 10LD 50 ,5LD 50 ,2.5LD 50 ,1.25LD 50 ,0.625LD 50 Fluorescence intensity was then measured and three biological replicates were set for each concentration gradient. The stability of the equation was demonstrated to be good.
Step two, gray value analysis is carried out by using imageJ software, and finally, the obtained gray value is drawn into a regression curve, and a regression equation is formed: y=0.01915x+0.002875 (R 2 = 0.9972). The method is used for determining the mouse LD with the minimum detection limit of 0.625 times of clostridium perfringens alpha toxin 50 Has higher sensitivity. The specific result is shown in figure 5 of the specification.
And thirdly, dividing the five dilutions of the detected toxin into five groups, performing three biological repetitions of each dilution, and analyzing the variation coefficient of the gray value result obtained by detection. Analysis shows that the results are lower than 15%, which indicates that the variation degree of the same sample in the same batch is low, and the established fluorescent silica microsphere toxin detection method has good stability. Specific results are shown in Table 1 attached to the specification.
Table 1. Repeatability test of silica microsphere fluorescence detection (n=3)
Example 4: detection of CPA concentration in food using silica microspheres
The effect of the detection technique established in this experiment was evaluated by performing an actual test on milk determined according to GB 4789.13-2012 to be free of clostridium welfare, i.e. the suitability and tamper resistance of the detection system for actual food products was tested. For milk, we separately took clostridium perfringens toxins low, medium, high concentrations (0.625 LD 50 , 2.5LD 50 ,10LD 50 ) And mixing them with 1mL of milk, respectively, and then mixing the mixture with antibody CPA C3 With fluorescent FITC antibody CPA N After the interaction of silica microspheres for one hour, milk is removed by washing, then the fluorescence detection experiment of the silica microspheres described above is carried out, the obtained fluorescence image is uploaded to APP, the fluorescence intensity is analyzed, the corresponding toxin concentration is obtained through conversion according to a standard regression equation, and the recovery rate is satisfactory, and is in the range of 80-108.8%. Specific results are shown in Table 2 attached to the specification.
TABLE 2 recovery of different alpha toxin concentrations in milk samples
Example 5: combination of detection method and smart phone
And the combination of the image processing technology and the smart phone is utilized, and the mobile phone APP application software is further manufactured through programming, so that the software program is applicable to all android smart phones. The method comprises the following steps of setting basic parameters: image name, average gray value and LD 50 Values. The specific operation is that the fluorescence picture obtained by detection is uploaded to the mobile phone APP to obtain the corresponding clostridial toxin concentration in real time. The specific result is shown in figure 6 of the specification.
In summary, in the developed system, the whole process is less than 90 minutes, and the detection limit is 0.625LD 50 CPA. The result shows that the silica microsphere combined smart phone CPA detection system is a sensitive, stable and convenient detection method, and provides a new method for detecting natural CPA in food.
The method for detecting clostridium perfringens alpha toxin based on the combination of the silica microspheres and the smart phone in real time can be realized by a person skilled in the art by referring to the content of the specification, properly changing the condition route and other links, although the method and the preparation technology of the invention have been described by the preferred embodiment examples, the related person can obviously change or recombine the method and the technical route described herein to realize the final preparation technology without departing from the content, the spirit and the scope of the invention. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be included within the spirit, scope and content of the invention.
Reference to the literature
1.Jang,Y.S.,et al.,Prevalence,toxin-typing,and antimicrobial susceptibility of Clostridium perfringens from retail meats in Seoul,Korea.Anaerobe,2020:p.102235.
2.Lacey,J.A.,et al.,In silico Identification of Novel Toxin Homologs and Associated Mobile Genetic Elements in Clostridium perfringens.Pathogens,2019.8(1).
3.Kumar,N.P.,N.V.Kumar,and A.Karthik,Molecular detection and characterization of Clostridium perfringens toxin genes causing necrotic enteritis in broiler chickens.Tropical Animal Health and Production,2019.51(9–10).
4.Oda,M.,et al.,Effect of erythromycin on biological activities induced by clostridium perfringens alpha-toxin.J Pharmacol Exp Ther,2008.327(3):p.934-40.
5.Takehara,M.,et al.,Granulocyte Colony-Stimulating Factor Does Not Influence Clostridium Perfringens alpha-Toxin-Induced Myonecrosis in Mice.Toxins(Basel),2019.11(9).
6.Takehara,M.,et al.,Clostridium perfringens alpha-toxin impairs granulocyte colony-stimulating factor receptor-mediated granulocyte production while triggering septic shock.Commun Biol,2019.2:p.45.
7.Takagishi,T.,et al.,Clostridium perfringens alpha-toxin impairs erythropoiesis by inhibition of erythroid differentiation.Sci Rep,2017.7(1):p.5217.
8.<Rapid Detection of Clostridium perfringens Type A Enterotoxin by Enzyme-Linked Immunosorbent Assay.pdf>.
9.<Detection of Clostridium perfringens alpha toxin using a capture antibody ELISA.pdf>.
10.<ENTEROTOXAEMIA IN GOATS.pdf>.
11.<Molecular Typing and Epidemiological Survey of Prevalence of Clostridium perfringens Types by Multiplex PCR.pdf>.
12.Baums,C.G.,et al.,Diagnostic multiplex PCR for toxin genotyping of Clostridium perfringens isolates.Veterinary Microbiology,2004.100(1-2):p.11-16.
13.Gurjar,A.A.,et al.,Real-time multiplex PCR assay for rapid detection and toxintyping of Clostridium perfringens toxin producing strains in feces of dairy cattle.Mol Cell Probes,2008.22(2):p.90-5.
14. Du Jige, et al, expression of clostridium perfringens alpha toxin mutants and immunoprotection assessment chinese veterinary journal 2019.039 (002): p.265-270,280.
15.Jige,D.,et al.,Three Copies Recombinant Expression and Immunogenicity Analysis of C-terminal of Clostridium perfringensαToxin.china animal husbandry&veterinary medicine, 2018。
Sequence listing
<110> university of Tianjin
<120> a method for visual detection of clostridium perfringens alpha toxin
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 247
<212> PRT
<213> Artificial sequence ()
<400> 1
His Met Trp Asp Gly Lys Ile Asp Gly Thr Gly Thr His Ala Met Ile
1 5 10 15
Val Thr Gln Gly Val Ser Ile Leu Glu Asn Asp Leu Ser Lys Asn Glu
20 25 30
Pro Glu Ser Val Arg Lys Asn Leu Glu Ile Leu Lys Glu Asn Met His
35 40 45
Glu Leu Gln Leu Gly Ser Thr Tyr Pro Gly Tyr Asp Lys Asn Ala Tyr
50 55 60
Asp Leu Tyr Gln Asp His Phe Trp Asp Pro Asp Thr Asp Asn Asn Phe
65 70 75 80
Ser Lys Asp Asn Ser Trp Tyr Leu Ala Tyr Ser Ile Pro Asp Thr Gly
85 90 95
Glu Ser Gln Ile Arg Lys Phe Ser Ala Leu Ala Arg Tyr Glu Trp Gln
100 105 110
Arg Gly Asn Tyr Lys Gln Ala Thr Phe Tyr Leu Gly Glu Ala Met His
115 120 125
Tyr Phe Gly Gly Ile Asp Thr Pro Tyr His Pro Ala Asn Val Thr Ala
130 135 140
Val Asp Ser Ala Gly His Val Lys Phe Glu Thr Phe Ala Glu Glu Arg
145 150 155 160
Lys Glu Gln Tyr Lys Ile Asn Thr Ala Gly Cys Lys Thr Asn Glu Asp
165 170 175
Phe Tyr Ala Asp Ile Leu Lys Asn Lys Asp Phe Asn Ala Trp Ser Lys
180 185 190
Glu Tyr Ala Arg Gly Phe Ala Lys Thr Gly Lys Ser Ile Tyr Tyr Ser
195 200 205
His Ala Ser Met Ser His Ser Trp Asp Asp Trp Asp Tyr Ala Ala Lys
210 215 220
Val Thr Leu Ala Asn Ser Gln Lys Gly Thr Ala Gly Tyr Ile Tyr Arg
225 230 235 240
Phe Leu His Asp Val Ser Glu
245
<210> 2
<211> 27
<212> DNA
<213> CPAm4
<400> 2
ggatcccata tgtggggggg ggggagg 27
<210> 3
<211> 26
<212> DNA
<213> CPAm4
<400> 3
ctcgagggat gggtcattac cctcgc 26
Claims (4)
1. A visual detection method for clostridium perfringens alpha toxin is characterized in that a prokaryotic expression CPA truncated protein is used for injecting animals to prepare antibodies to CPA N After the antibody is labeled by fluorescein isothiocyanate, the capture antibody CPA is obtained C3 The coupling silica microspheres are used for capturing alpha toxin in food, and the concentration of the alpha toxin of the sample to be detected can be obtained in real time after the fluorescence picture obtained by detection is uploaded to the mobile phone APP;
the prokaryotic expression CPA protein truncated CPA N Comprises two mutation sites D56G and D130G of CPA protein, wherein the CPA comprises a polypeptide sequence of the CPA protein N The truncated body is a protein sequence of SEQ ID No. 1;
said prokaryotic expression CPA protein truncated CPA N The construction of (a) and the preparation of antibodies comprising the steps of:
(1) CPA protein truncate CPA N Is constructed by the following steps: because CPA protein has toxicity and lethality, in order to facilitate the preparation of subsequent antisera, CPA mutants are used in experiments to eliminate the toxic effect on immunized animals; plasmid pET30a-CPA using 4-amino acid mutant m4 And a C-terminal three-copy tandem plasmid pET30a-CPA C3 The method comprises the steps of carrying out a first treatment on the surface of the In CPA m4 Primer CPA is designed on the basis m4 Dele TM-F, SEQ ID No.2 and CPA m4 Deletion of transmembrane Domain by delete TM-R, SEQ ID No.3 to obtain N-terminal truncated plasmid pET30a-CPA N The plasmid contains only the two amino acid mutations D56G, D130G;
(2) Antibody preparation: the constructed pET30a-CPA N pET30a-CPA C3 The prokaryotic expression vector converts competent cells of escherichia coli BL21 (DE 3), IPTG induces and purifies recombinant proteins; immunization of rabbits three times with 1mg/mL protein amount resulted in anti-CPA C3 And CPA (CPA) N Purifying polyclonal antibody by rabbit serum and Saturated Ammonium Sulfate (SAS) precipitation, and detecting antibody titer by Western-blot and ELISA;
(3) CPA using semi-permeable membrane process N The fluorescence intensity of the microsphere detected by a fluorescence microscope is the concentration of the corresponding clostridium alpha toxin by utilizing the double antibody sandwich principle of antigen-antibody combination.
2. The method for visual detection of clostridium perfringens alpha toxin according to claim 1 wherein said CPA protein truncate silica microsphere is coupled comprising the steps of:
(1) Quantification of clostridium perfringens alpha toxin using virulence substitution experiment-lecithin hydrolysis experiment, and final measured natural CPA concentration of 10LD 50 ;
(2) Activation of silica microspheres: carboxylated silica microsphere surface coupling CPA N Polyclonal antibody, adding coupling agent N-hydroxysuccinimide (NHS) and carbodiimide (EDC) with final concentration of 10mg/mL, and finally sealing;
(3) Condition optimization of silica microsphere detection experiment: comprising optimally coupled CPA C3 Conditions of antibody, optimal blocking conditions, optimal coupling conditions of detection antibody; finally, the optimal conditions for the fluorescence detection test, namely, the CPA of the capture antibody at 25 ℃ and 0.1mg/ml, are determined according to the experimental data C3 After 2h interaction with activated silica microspheres, blocking with 5% BSA overnight at 4℃and finally detecting alpha toxin and 0.2mg/ml FITC-CPA at 37℃the next day N And (3) performing interaction with the silica microspheres coupled with the capture antibody for 1h, so as to perform detection by a fluorescence microscope.
3. The method for visual detection of clostridium perfringens alpha toxin according to claim 1 wherein said alpha toxin capture standard curve is established with a detection line sensitivity of 0.625LD 50 The detection time was 90min.
4. A method of visual detection of clostridium perfringens alpha toxin according to claim 3 wherein said establishment of alpha toxin capture standard curve comprises the steps of:
(1) Establishment of a standard curve: performing double gradient dilution on the natural clostridium perfringens alpha toxin, wherein the total dilution is 5, each dilution is 3 biological repetitions, and then obtaining a group of fluorescence pictures by detecting the fluorescence intensity of the silicon dioxide microspheres coupled to the FITC labeled antibodies;
(2) The fluorescent intensity in the picture is subjected to gray value analysis, the picture is firstly converted into an 8-bit gray image, background interference is eliminated, brightness values in all image areas are selected for carrying out average analysis, the average gray value of the corresponding image is finally obtained, the data are arranged to obtain a regression equation Y=0.01915X+0.002875, R 2 = 0.9972; wherein X represents LD 50 Y represents an average gray value;
(3) Programming an image processing technology into an APP (application) of a smart phone, firstly analyzing an RGB value of a picture, then converting the RGB color value into hexadecimal color code gray to obtain a gray value of the image, and finally utilizing an IF (IF-based) algorithm to correspond different gray value ranges to CPA (complex programmable logic) concentration; after APP is prepared, the corresponding CPA concentration can be directly obtained by uploading the fluorescence image.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883292.3A CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010883292.3A CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111983240A CN111983240A (en) | 2020-11-24 |
CN111983240B true CN111983240B (en) | 2023-11-21 |
Family
ID=73441499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010883292.3A Active CN111983240B (en) | 2020-08-27 | 2020-08-27 | Visual detection method for clostridium perfringens alpha toxin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111983240B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103941004A (en) * | 2014-01-25 | 2014-07-23 | 山东农业大学 | Clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method |
CN107596361A (en) * | 2017-09-12 | 2018-01-19 | 浙江海隆生物科技有限公司 | Subunit vaccine of bovine A-type clostridium perfringens and preparation method and application thereof |
KR101823353B1 (en) * | 2016-09-02 | 2018-01-31 | 롯데푸드 주식회사 | Method for detecting rapidly botulium toxin A, B, E and Clostridium perfringens alpha toxin and detection kit |
CN108315451A (en) * | 2018-03-29 | 2018-07-24 | 河北出入境检验检疫局检验检疫技术中心 | Primer and probe for detecting C.perfringens and its application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8574590B2 (en) * | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
AU2014365888B2 (en) * | 2013-12-16 | 2018-12-06 | Merck Patent Gmbh | Survivin-directed cancer vaccine therapy |
-
2020
- 2020-08-27 CN CN202010883292.3A patent/CN111983240B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103941004A (en) * | 2014-01-25 | 2014-07-23 | 山东农业大学 | Clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method |
KR101823353B1 (en) * | 2016-09-02 | 2018-01-31 | 롯데푸드 주식회사 | Method for detecting rapidly botulium toxin A, B, E and Clostridium perfringens alpha toxin and detection kit |
CN107596361A (en) * | 2017-09-12 | 2018-01-19 | 浙江海隆生物科技有限公司 | Subunit vaccine of bovine A-type clostridium perfringens and preparation method and application thereof |
CN108315451A (en) * | 2018-03-29 | 2018-07-24 | 河北出入境检验检疫局检验检疫技术中心 | Primer and probe for detecting C.perfringens and its application |
Non-Patent Citations (3)
Title |
---|
A sandwich duplex immuno PCR for rapid and sensitive identification of Clostridium perfringens alpha and enterotoxin;Shreya Das et al.;《Anaerobe》;全文 * |
产气荚膜梭菌α毒素C末端的二拷贝串联表达与免疫原性分析;杜吉革;王磊;薛麒;朱真;李启红;印春生;姚文生;康凯;陈小云;;中国兽医杂志(第01期);全文 * |
聚合酶链式反应-单链构象多态性分析法检测大肠腺瘤及大肠癌APC基因突变;王艳, 刘士良, 郝冬梅, 庄宝珠, 张学, 傅宝玉;中华肿瘤杂志(第04期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN111983240A (en) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103497252B (en) | For the single domain heavy chain antibody L5-78 of Listeria monocytogenes | |
CN105906714B (en) | A kind of preparation and application of brucellosis specific fusion protein antigen | |
CN108267582A (en) | Infection of Toxoplasma Gondii colloidal gold immuno-chromatography test paper strip and preparation method thereof | |
CN112574320B (en) | Fusion protein antigen for diagnosing brucellosis of dog | |
Xu et al. | Rapid detection of Campylobacter jejuni using fluorescent microspheres as label for immunochromatographic strip test | |
CN102731615A (en) | Detection reagent and detection method for PRRSV | |
CN109053883B (en) | Binding protein of NS1 protein | |
CN110327460A (en) | Streptococcus suis-Haemophilus parasuis bigeminy subunit vaccine and preparation method | |
CN110133284A (en) | Proteantigen and its encoding gene and they identifying the application in mycoplasma hyopneumoniae inactivated vaccine antibody and natural infection antibody | |
CN105061602B (en) | For detecting fusion protein, the preparation method and application of anti-pig enterotoxigenic escherichia coil antibody | |
CN109239341B (en) | Indirect ELISA kit for detecting bovine haemolytic mannheimia antibody and application thereof | |
CN105755118A (en) | Method for quickly detecting vibrio parahaemolyticus by aid of immunomagnetic beads and loop-mediated isothermal amplification processes | |
CN107304231B (en) | Mycobacterium tuberculosis fusion protein and application thereof | |
CN110483625A (en) | A kind of Mycoplasma bovis imagination albumen MbovP732 and its application | |
CN111983240B (en) | Visual detection method for clostridium perfringens alpha toxin | |
Jiao et al. | Lateral flow immunochromatographic assay for competitive detection of crustacean allergen tropomyosin using phage-displayed shark single-domain antibody | |
CN101367870A (en) | Bovine rotavirus recombinant VP6 protein antigen and method of preparing the same | |
CN110476065A (en) | Diagnosis | |
CN111596070A (en) | Application of portunus trituberculatus tropomyosin allergy detection reagent | |
CN109856396B (en) | Enzyme linked immunosorbent assay kit for detecting foot and mouth disease virus infection antibody and application thereof | |
CN114933639B (en) | African swine fever virus p72N epitope protein and preparation method and application thereof | |
CN110376388A (en) | A kind of haemophilus parasuis antibody detection method and its kit | |
CN108982847A (en) | A kind of indirect ELISA detection method for the duck reovirus leading to duck spleen necrosis | |
CN107664694A (en) | A kind of ELISA kit based on E2 Protein Detection pig atypia pestivirus antibody | |
CN108893476A (en) | Babesiamicrofti 2D97 antigen protein and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |